Sign Up to like & get recommendations! 1
Published in 2022 at "Molecular oncology"
DOI: 10.1002/1878-0261.13199
Abstract: Drug resistance remains a major challenge in the clinical treatment of gastrointestinal stromal tumors (GISTs). While acquired on-target mutations of mast/stem cell growth factor receptor (KIT) kinase is the major resistance mechanism, activation of alternative… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4630
Abstract: Gastrointestinal stromal tumors (GIST) are mesenchymal tumors in the intestinal tract originating from a precursor to the interstitial cells of Cajal, which plays a role in gastric motility. The preoperative diagnosis of GIST may be… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5471
Abstract: We compared endoscopic “calabash” ligation and resection (ECLR) and endoscopic submucosal excision (ESE) in treating endophytic gastric stromal tumors (GSTs) ≤15 mm in diameter originating from the muscularis propria. read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24514
Abstract: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Previous literature has suggested that small intestine GISTs are more aggressive than gastric GISTs. Our primary objective was to compare the… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27042
Abstract: The controlling nutritional status (CONUT) score is associated with the postoperative outcomes in various types of tumors, and its prognostic role in gastrointestinal stromal tumors (GISTs) needs to be clarified. read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Abdominal Radiology"
DOI: 10.1007/s00261-019-02209-7
Abstract: To identify the predictors of malignancy on CT for the evaluation of gastrointestinal stromal tumors (GIST) by correlating CT findings with the mitotic index in order to propose a “CT-based predictive model of Miettinen index.”… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Abdominal Radiology"
DOI: 10.1007/s00261-021-02998-w
Abstract: Sex cord-stromal tumors of the ovary (SCST) are uncommon ovarian tumors arising from sex cord and/or stromal cells of the ovaries. They may be nonfunctional and asymptomatic or functional presenting with hyperestrogenic, hyperandrogenic or cushingoid… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Gastric Cancer"
DOI: 10.1007/s10120-018-00908-6
Abstract: ObjectivesTo determine CT features that can identify gastrointestinal stromal tumors (GISTs) among gastric sub-epithelial tumors (SETs) and to explore a practical scoring method.MethodsSixty-four patients with gastric SETs (51 GISTs and 13 non-GISTs) from hospital I… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Cancer and Metastasis Reviews"
DOI: 10.1007/s10555-019-09818-0
Abstract: Gastrointestinal stromal tumors (GISTs) are increasingly recognized as having diverse biology. With the development of tyrosine kinase inhibitors molecularly matched to oncogenic KIT and PDGFRA mutations, GISTs have become a quintessential model for precision oncology.… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-019-00324-8
Abstract: Little is known about the sporadic coincidence of gastrointestinal stromal tumors (GISTs) with second primary tumors (SPTs). The aim of this study is to clarify if there is a clinicopathologic correlation responsible for the synchronous… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-019-0486-5
Abstract: SummaryThe approval of imatinib for the treatment of patients with gastrointestinal stromal tumor has (GIST) revolutionized the treatment in the adjuvant setting and metastatic disease. Imatinib is an inhibitor of the receptor tyrosine kinases KIT… read more here.